Intravenous immunoglobulin treatment in multifocal motor neuropathy

Journal of Clinical Immunology

Volumn 30, Issue SUPPL. 1, 2010, Pages

  Van Der Pol, W Ludo ^a   Cats, Elisabeth A ^a   Van Den Berg, Leonard H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Conduction block; GM1 antibodies; Intravenous immunoglobulin; Multifocal motor neuropathy

Indexed keywords

CYCLOPHOSPHAMIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM1 ANTIBODY; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; PREDNISONE; SODIUM CHANNEL; AUTOANTIBODY; AUTOANTIGEN; GANGLIOSIDE GM1; HLA DRB1 ANTIGEN; HLA-DRB1*15 ANTIGEN;

ACUTE MOTOR AXONAL NEUROPATHY; BINDING AFFINITY; CLINICAL FEATURE; DISEASE COURSE; DRUG MECHANISM; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOLOGY; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; MULTIFOCAL MOTORT NEUROPATHY; NERVE BLOCK; NERVE EXCITABILITY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REVIEW; SEROLOGY; ADULT; AGED; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; FEMALE; FORECASTING; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NERVE CONDUCTION; PATHOLOGY; PERIPHERAL NERVE; YOUNG ADULT;

ADULT; AGED; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; FEMALE; FORECASTING; G(M1) GANGLIOSIDE; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NEURAL CONDUCTION; PERIPHERAL NERVES; YOUNG ADULT; HLA-DRB1 CHAINS;

EID: 77956188374     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9408-3     Document Type: Review

References (20)

1. Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73-78
2. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol. 2001;115:4-18.
3. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol. 2005;4:309-319
4. Corbo M, Abouzahr MK, Latov N, Iannaccone S, Quattrini A, Nemni R, et al. Motor nerve biopsy studies in motor neuropathy and motor neuron disease. Muscle Nerve. 1997;20:15-21.
5. Taylor BV, Dyck PJ, Engelstad J, Gruener G, Grant I, Dyck PJ. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol. 2004;63:129-137
6. Kiernan MC, Guglielmi JM, Kaji R, Murray NM, Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain. 2002;125: 664-675
7. Van Asseldonk JT, Van den Berg LH, Kalmijn S, Van den Berg- Vos RM, Polman CH, Wokke JH, et al. Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2006;77:743-747
8. Priori A, Bossi B, Ardolino G, Bertolasi L, Carpo M, Nobile- Orazio E, et al. Pathophysiological heterogeneity of conduction blocks in multifocal motor neuropathy. Brain. 2005;128:1642-1648
9. Priori A, Cinnante C, Pesenti A, Carpo M, Cappellari A, Nobile- Orazio E, et al. Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. Brain. 2002;125:2481-2490
10. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complementmediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci. 2007;27:3956-3967
11. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591-2625
12. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents antiganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131:1197-1208
13. Uetz-von Allmen E, Sturzenegger M, Rieben R, Rihs F, Frauenfelder A, Nydegger UE. Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. Eur Neurol. 1998;39:103-110
14. Phongsisay V, Susuki K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol. 2008;205:101-104
15. Terenghi F, Allaria S, Scarlato G, Nobile-Orazio E. Multifocal motor neuropathy and Campylobacter jejuni reactivity. Neurology. 2002;59:282-284
16. Sutedja NA, Otten HG, Cats EA, Piepers S, Veldink JH, van der Pol WL, et al. Increased frequency of HLA-DRB1.*15 in patients with multifocal motor neuropathy. Neurology. 2010;74:828-832
17. De Angelis MV, Notturno F, Caporale CM, Pace M, Uncini A. Polymorphisms of CD1 genes in chronic dysimmune neuropathies. J Neuroimmunol. 2007;186:161-163
18. Terenghi F, Allaria S, Nobile-Orazio E. Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst. 2006;11:67-71.
19. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002;59:S13-21.
20. Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA. 2009;106:4788-4792